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The  measurement  of  human  insulin  and  its synthetic  analogues  in  biological  matrices  has  become
increasingly  important  not  only  in clinical  ﬁelds  but also in  doping  control.  The  use  of  insulin and
its  analogues  have  been  included  in the  list  of prohibited  substances  published  by  the  World  Anti-
Doping  Agency  (WADA).  This  study  describes  a qualitative  method  for detection  of  insulin  analogues
(lispro,  aspart,  glulisine,  glargine,  degludec,  detemir)  in  human  urine.  The  sample  preparation  consistseywords:
nsulins
oping control
mmunafﬁnity puriﬁcation
ltraﬁltration
of  a preconcentration  step  using  ultraﬁltration  followed  by  an  immunoafﬁnity  extraction  with  an  anti-
body  precoated  ELISA  plate.  The  obtained  extracts  are  analyzed  by  conventional  high-performance  liquid
chromatography–electrospray  tandem  mass  spectrometry  (LC-ESI–MS/MS).  The  limits  of  detection  range
between 10 pg/ml  and  150 pg/ml.  The  applicability  of  the method  was  proven  by  the  analysis  of  real  urine
samples  obtained  from  diabetic  patients  treated  with  synthetic  insulin  analogues.
© 2018  Elsevier  B.V.  All  rights  reserved.. Introduction
Insulin is a double-chain peptide with a molecular weight
f ∼6 kDa. Apart from the therapeutic importance of its artiﬁcially
esigned analogues (Lispro, Gluisine, Aspart, Detemir, Glargine,
egludec), their potential performance enhancement effects for
thletes have also been discussed [1]. Therefore all types of insulins
re included in the list of prohibited substances by the World Anti-
oping Agency (WADA) [2].
Several mass spectrometry based assays have been reported
or the determination of insulins in urine [3–7] and serum/plasma
atrices [7–16]. Because of their low urinary and plasma con-
entrations (<1 ng/ml) a variety of sample preparation techniques
ave been described to reach these low concentration-levels being
mmunoafﬁnity puriﬁcation (IAP) using IAP-columns [3–5,17], IAP
sing magnetic beads [6,9,11,12,18] or solid phase extraction (SPE)
10,14,19,20]. Prior to IAP, a sample volume reduction step is often
ncluded and can either consist of SPE or [3–6] or molecular weight
MW)  based centrifugal ﬁltration [7,11].
The aim of this work is to expand the possibilities to isolate
nd sensitively measure synthetic insulins in urine. Human insulin
∗ Corresponding author.
E-mail address: peter.judak@ugent.be (P. Judák).
ttps://doi.org/10.1016/j.jpba.2018.02.024
731-7085/© 2018 Elsevier B.V. All rights reserved.selective ELISA assays are also commercially available and used
for clinical applications [21,22], however to the best of our knowl-
edge their use in combination with mass spectrometry for synthetic
urinary insulin determination has not been described yet.
The present study introduces a new strategy which consists of
sample preparation using ELISA plate based IAP in combination
with MW based centrifugal ﬁltration and subsequent mass spec-
trometric detection.
2. Experimental
2.1. Chemicals and materials
Insulin Lispro was  purchased from Eli Lilly (Indianapolis, USA),
Insulin Aspart, Insulin Glulisine, Insulin Glargine, Insulin Detemir,
Insulin Degludec, Insulin Bovine, Bovine Serum Albumin (BSA)
and Betamethasone were purchased from Sigma Aldrich (Bornem,
Belgium). Insulin Glargine Metabolite was  a kind gift of the Cologne
anti-doping laboratory. Mercodia isoInsulin kit, including Mer-
codia wash buffer was purchased from Bio-Connect Diagnostics
(Huissen,Nederland), Amicon Ultra 3 kDa 0.5/15 ml  centrifugal ﬁl-
ters were purchased from Merck (Darmstadt, Germany). LC–MS
grade acetonitrile (ACN) and water were obtained from J.T. Baker
(Deventer, Netherlands), formic acid (HCOOH) from Fisher Chem-
ical (Madrid, Spain). Stock and working solutions were prepared
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nd stored in polypropylene microcentrifugal vials, type Eppen-
orf (Eppendorf, Hamburg, Germany). For performing the dilution
teps polypropylene pipette tips (Eppendorf, Germany) were used.
.2. Instrumentation
The HPLC system consisted of a Dionex Ultimate 3000 LC
Thermo Scientiﬁc, Bremen, Germany) equipped with a degasser,
ionex Ultimate 3000 UPLC pump, an autosampler thermostated at
5 ◦C and a thermostated (40 ◦C) column compartment. A Waters
PLC Peptide BEH C18 (2.1*50 mm)  1.7 m particle size column
nd a Waters Acquity Protein BEH C18 (2.1*5 mm)  precolumn were
sed for LC separation. Mobile phases were A: H2O (containing
.2 v/v% formic acid) and B: acetonitrile (containing 0.2 v/v% formic
cid). For the separation the following gradient elution was used:
% B hold for 0.5 min  and increased to 15% in 1 min, then further
ncreased to 35% in 4 min  and held there for 1.5 min, increased
o 45% in 8.5 min, increased to 95% in 8.6 min  and held there for
.5 min, decreased to 1% B in 9.2 min  and equilibrated for 2.9 min,
iving a total runtime of 12.1 min. The ﬂow rate was 0.3 ml/min.
The LC-system was coupled with a TSQ Vantage triple
uadrupole mass spectrometer (Thermo Scientiﬁc, Bremen,
ermany). The mass spectrometer was equipped with an electro-
pray ionization source. The parameters of the ion source were
he following: spray voltage 3.5 kV, capillary temperature 350 ◦C;
heath gas 50, auxiliary gas 50, collision gas pressure 3mTorr. The
ifferent collision energies and S-lens settings are summarized in
able 1.
.3. Preparation of solutions used for sample preparation and
alidation
All peptide stock standard solutions were prepared at
.1 mg/ml  using a mix  of A-water, B-acetonitrile, C-formic acid
a:b:c,60/40/0.02 v/v%) and were stored at −20 ◦C. Working solu-
ions (100 and 50 ng/ml) were prepared using the same mixture and
lso contained BSA at a concentration of 5 g/ml. Bovine insulin was
sed as internal standard. A solution was prepared at the concen-
ration of 1 g/ml using the mix  of A-water, B-acetonitrile, C-formic
cid (a:b:c, 60/40/0.02 v/v%) and was stored at −20 ◦C. A mixture of
-water, B-acetonitrile, C-formic acid (a:b:c,65/35/0.02 v/v%) con-
aining 5 g/ml BSA and 1 g/ml Betamethasone was prepared as
lution buffer. Betamethasone was included in the elution buffer
o control the precision of the injection volumes of the liquid chro-
atographic autosampler.
able 1
olecular formulas, monitored precursor and product ions, and mass spectrometric param
Molecular Formula Molecular weight
Lispro C257H383N65O77S6 5807
Aspart C256H381N65O79S6 5826
Glulisine C258H384N64O78S6 5823 
Glargine C267H404N72O78S6 6063 
Glargine Metabolite C255H380N64O76S6 5750
Detemir C267H402N64O76S6 5917 
Degludec C274H411N65O81S6 6104 
Human C257H383N65O77S6 5807
Bovine C254H377N65O75S6 5733 Biomedical Analysis 153 (2018) 76–81 77
2.4. Administration study
As a proof of concept, urine samples from seven diabetes
patients who were treated with different forms of insulin medi-
cation were obtained from the Department of Internal Medicine
(Endocrinology) and Hematology of the Ghent University Hospital,
with the approval of the Ethical Committee of the Ghent Univer-
sity (reference: 2010/314). Samples were stored at −80 ◦C awaiting
analysis. Two  excretion urine samples that were distributed among
doping control laboratories by WADA were also analyzed.
2.5. Sample preparation
To 15 ml  urine 2 l of ISTD Bovine insulin solution was  added.
The pH of the sample was adjusted to ∼ 7 by adding 1 ml  of 3.75 M
Tris/HCl buffer. The sample was vortexed and centrifuged for
20 min  at 4000 rcf. The supernatant was  then transferred in an
Amicon Ultra 15 ﬁlter and centrifuged at 4000 rcf for 90 min. The
retentate was transferred in an Amicon Ultra 0.5 ﬁlter and cen-
trifuged for 40 min  at 10000 rcf. Finally the retentate (∼50 l) was
transferred into an ELISA well. The ELISA-plate was incubated for
1.5 h at room temperature with gentle shaking. The wells were
washed 5 times with the diluted Mercodia wash buffer solution
(prepared according to the speciﬁcation of the manufacturer) after
incubation. By the addition of 60 l of elution buffer the analytes
were eluted and transferred to a polypropylene tube for LC–MS
analysis.
2.6. Validation
Validation was  carried out according to Eurachem Guidelines
[23]. Ten different blank urine samples were collected for the vali-
dation of the method in a representative way covering a pH range
of 5.1–6.9 and density of 1.011–1.0255 g/cm3.
Each urine sample was spiked at 0.15, 0.075, 0.05, 0.025,
0.01 ng/ml to determine the LOD of the method, which was consid-
ered the lowest concentration at which the targeted analyte could
be detected in all ten urine samples using two  diagnostic ion tran-
sitions with a signal-to-noise ratio greater than 3 and a retention
time difference of less than 0.2 min  to the reference. To obtain con-
centrations of 0.15, 0.075, 0.05, 0.025 ng/ml, 15 ml of blank urine
was spiked from the 100 ng/ml working solution by the addition
of 22.5, 11.25, 7.5, 3.75 l respectively, to obtain peptide concen-
trations of 0.01 ng/ml 15 ml  of blank urine was  spiked from the
50 ng/ml working solution by adding 3 l.
Retention time stability was  assessed by comparing the reten-
tion time of the target analytes after extraction and without
extraction in neat standard solutions.
eters (collision energies, and S-lens settings) of the investigated insulin analogues.
 (Da) Precursor Ion Product Ion (Collision E(eV), S-Lens)
1162,6 216,8 (36;150)
968,9 216,8 (34;150)
1165,5 135,9 (36;150)
972,2 135,9 (39;150)
1165,88 328(39;150)346(39;150)
867,2 135,7(33;150)
959,5 225,8(35;150)135,9(40;150)
1151,4 225,8(44;150)
1184,7 357(41;180)454,3(35;150)
1222,12 310(39;150)641,6(42;150)
968,9 226 (36;150)
1162,6 226 (44;150)
956,8 135,8 (30;150)
956,8 226 (35;150)
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Table 2
LODs and recoveries of the validated method.
Insulins Lispro Aspart Glulisine Glargine Glargine Metabolite Detemir Degludec
75 
20 
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tLOD (pg/ml) <10 50 50 
Recovery (%) 28 22 21 
Selectivity was tested during the validation procedure to probe
or interference with the MSMS  transitions of the product ions at
he expected retention times of the different insulin analogues.
or this reason, during the validation a mixture prepared from
ther doping classes (in total 327 substances) was processed. Also
ll 10 blank urines spiked only with the internal standard were
hecked. To check if transitions of the insulin analogues interfere
ith each other, standard solutions of each analogue (50 ng/ml)
ere injected.
Recoveries were estimated by comparing the peak area of the
arget compounds in 10 urines spiked before the extraction of the
amples with the peak area of samples spiked after the extraction.
hese samples were spiked at the concentration of 50 pg/ml.
Carry-over was assessed by injecting blank samples (solvent
sed for elution) after each urine sample during the validation
rocess.
. Results and discussion
.1. Method development
.1.1. Sample preparation
Because of their low urinary concentrations (<1 ng/ml) insulins
re often extracted starting from a large volume of urine. Generally
etween 25 ml  [3,4] and 5 ml  [5,6,18] of urine is reduced to ∼1 ml
o facilitate incubation with antibodies. To reduce these volumes,
PE is often applied [3–6]. Because in our approach 15 ml  of urine
as concentrated, SPE often resulted in blocked cartridges and
ow recoveries (<50%/data not presented). Another useful approach
o preconcentrate peptides is the employment of MW ﬁltration
Fig. 1. Chromatographic separation of H50 50 150
23 10 11
(MWF). This technique has already been found successful for the
analysis of erythropoietins (EPO) [24] and for the preconcentration
of insulins from blood [7,11] and urine matrices [7]. Comparing
the SPE with the MWF  approach showed that the latter was more
robust regarding recovery and blockage, despite the fact that the
low MW cut-off (3 kDa) ﬁlters made the centrifugation time rela-
tively long (∼2 h). An additional beneﬁt of using the MWF  is that
after preconcentration the retentate (approximately 50 l) can be
directly loaded into the wells of the ELISA-plates whereas an SPE
step requires an additional evaporation and redissolution step.
Antibody-extraction of insulins can be performed in different
ways. Although better recoveries have been achieved by using
immuno afﬁnity chromatography (IAC) (∼80% for the short act-
ing analogues) [4], the batch mode use of magnetic beads coated
with antibodies (∼30% for the short acting analogues) has been
favored due to its simple protocol. [6,9,11,12,18] Next to the above
described techniques, immunoassays where antibodies are immo-
bilized in wells of a plate are also commercially available. This
approach has already been successfully applied in the ﬁeld of dop-
ing control for the puriﬁcation of erythropoietin from urine [25].
The use of plates with human insulin-speciﬁc antibodies is more
widespread in clinical applications to investigate hypoglycemia and
their limitations and ability to detect synthetic insulin analogues
have been evaluated in previous studies [21,22]. These results show
high variations and reveal that many of these assays fail to detect
the analogues. In this study Mercodia isoInsulin kit was used and in
agreement with earlier results showed sufﬁcient cross reactivity to
all the investigated insulin analogues [22]. Therefore it is an appro-
priate alternative of the magnetic bead approach. Reproducible
results with acceptable recovery were achieved (Table 2), allow-
uman insulin and its analogues.
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Table  3
The collected excretion samples with indication of the administered insulin analogue, dose, elapsed time between administration and sample collection and the results of
the  analysis. (*the detection of Glargine was  covered by the metabolite of Glargine).
Sample Administered Analogue Dose T  (hours) Detection
WADA 1 Lispro 12IU/0,42mg- –
√
WADA 2 Lispro 12IU/0,42mg- –
√
Patient 1 Aspart 6 IU/0,21 mg 4
√
Patient 2 Glulisine 12,4 IU/0,44 mg 3
√
Patient 3 Glulisine 16 IU/0,56 mg  3
√
Glargine* – –
√
Patient 4 Aspart 3IU/0,11 mg 12
√
Patient 5 Glulisine Continous pump –
√
Patient 6 Aspart 10 IU/0,35 mg  4
√
12IU/
√
10 IU/
12IU/
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Patient 7 Aspart 
Glargine* 
ng to reach the required detection limits (see validation section)
n all analyzed samples.
One of the key aspects of the method development phase was
he effort that has been made to avoid sample losses during sample
reparation due to the adsorptive nature of the peptide molecules
escribed by numerous researchers [11,20,26–30]. Several acidic
lution buffers were tested with increasing percentage of organic
olvents and with the inclusion of BSA as a carrier protein. Chang-
ng the character of the elution buffer prompted the analytes to
eside preferentially in the buffer and not to stick to the walls of
PLC vials, resulting in signiﬁcantly increased recoveries. Even-
ually the mixture of A-water, B-acetonitrile, C-formic acid (a:b:c,
5/35/0.02 v/v%), containing 5 g/ml BSA was found to be optimal.
.1.2. Liquid chromatography-Mass spectrometry
Besides the great differences in sample preparation (see Intro-
uction), the mass spectrometric platforms used by several
esearch groups differ as well. Detection can be accomplished
sing triple quadrupole [3–5,10,11,14,17,19,20], high resolu-
ion mass spectrometers [6,7,12,13] coupled to conventional LC
3,4,13,17,19] or nano-LC instruments [5–7,9,11,12,18]. Applica-
ions using the nano chromatographic systems enabled to reach
he lowest detection limits in urinary matrix [6,7], however there
re still challenges with their use, including increased costs, com-
licated troubleshooting and longer chromatographic runs. [31]
herefore in this work conventional LC–MS/MS was preferred for
etection.
The applied gradient allowed chromatographic separation of
nsulin Detemir and Degludec from the other analytes due to their
ore apolar character, whereas Aspart, Glulisine, Lispro, Human
nsulin, Glargine and its metabolite showed very similar chromato-
raphic behavior (Fig. 1). As reported earlier the analytical column
ad to be conditioned before the ﬁrst use to deactivate remaining
ilanol groups, which can inhibit the recoveries of the insulins. [32]
In addition to the chromatographic retention times the differen-
iation of the analogues was accomplished based on their speciﬁc
S/MS  spectra. The selected ion transitions were very similar to
hose of previous studies, however in most cases the differentia-
ion of the analogues was not only based on one precursor-product
on combination. For example, to distinguish human insulin from
nsulin Lispro the diagnostic m/z 226 and m/z 217 ions were not only
btained by the fragmentation of the ﬁve-fold protonated precursor
on as in earlier studies [3–6,9,11,12,18], but also by fragmentation
f the six-fold protonated precursor ion.
.1.3. Method validation
The validated method, presented in this paper shows good sen-
itivity and is capable of detecting 5 out 7 of the insulins using
wo precursor-daughter ion transitions at the current minimum
equired performance limit (MPRL) of 50 pg/ml. Table 2 summa-0,42 mg  12
0,35 mg  3
√
0,42 mg  10
√
rizes the results of the reached detection limits. These LODs were
in the same order of magnitude of previous studies where 25 ml
of urine was extracted and the short- and long acting analogues
were not incorporated in the same method [3,4]. As already men-
tioned in the previous paragraph, lower LODs have been achieved
using nano-liquid chromatography coupled to nano-scale mass
spectrometry [6,7]. The current method allows the use of a more
affordable and robust instrumentation and incorporates both the
rapid- and the long acting insulin analogues in a single method.
Only one precursor-product ion transition of insulin Degludec (932-
641) could be measured at the required level of 50 pg/ml. This
can be explained by the absence of a second ion transition that
can be measured sensitively and by the low recovery of this com-
pound which was  also reported by Thomas et al. [7]. Probably, the
more complex structure of this analogue; the presence of fatty acid
groups, prevent efﬁcient binding to the antibodies. This limitation
does not hinder the screening of this analogue, however for conﬁr-
mation purposes the search for possible metabolites is needed to
obtain more identiﬁcation points. The measurement of only one ion
transition (867-135) of insulin Glargine resulted in a detection limit
below 50 pg/ml. However, targeting one of its earlier characterized
metabolites [3] provided ion transitions that could be sensitively
measured and cover for the detection of insulin Glargine misuse.
Assessing the selectivity of the method showed no interfering
peaks at the expected retention times of the analytes. However, it
has to be noted that a small interference with the ion transition of
insulin Aspart (∼5%) was observed when insulin Glulisine at con-
centrations higher than 50 ng/ml was injected. It was  due to the
fact that the fragmented precursor ions of Aspart and Glulisine have
masses with a difference smaller than ∼0.5 Da and the low resolu-
tion mass spectrometer with the used settings only allowed unit
resolution. Nevertheless, for conﬁrmation purposes the analysis
of more selective ions or the reduced forms (B-chain) are recom-
mended [4,18].
The results of the recovery test are listed in Table 2. Ana-
lyte recoveries concerning the centrifugal ﬁltering followed by the
immunoafﬁnity puriﬁcation varied between 10 and 28%. These val-
ues were lower than the ones obtained by other researchers varying
between (16–109%) [3–7,18], however were still satisfactory to
reach the required detection limits.
No carryover was  present in the blank samples injected after the
urine samples. Evaluating the retention time criteria showed that
all analogues met  the set requirement.
3.1.4. Results of the excretion study
The proof of concept was shown by applying the method to urinesamples obtained from diabetic patients who were treated with
insulin Lispro, Glulisine, Aspart and Glargine analogues. Table 3
summarizes the type and dose (IU stands for international unit) of
the administered insulin, the elapsed time between injection and
80 P. Judák et al. / Journal of Pharmaceutical and Biomedical Analysis 153 (2018) 76–81
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tig. 2. Examples of chromatograms of the analyzed excretion samples, showing th
ontrol samples (spiked at 50 pg/ml).
ample collection and the outcome of measurements. The devel-
ped approach enabled us to detect all analogues in the collected
amples. Insulin Lispro could also be detected in the external quality
ssessment samples (EQAS) sent by WADA to several doping lab-
ratories to monitor the capacities to correctly identify and report
amples containing insulin Lispro. Later, the estimated concen-
ration of Lispro in the samples (50 and 30 pg/ml) has also been
evealed by WADA, which was a good indicator of the required
ensitivity and was met  by our developed strategy.
In accordance with earlier reported studies the long-acting ana-
ogue Glargine in its intact form could not be detected [3]. In Fig. 2
xamples of detected analogues are presented. For each analogue at
east two SRM transitions were used to provide unequivocal proof
or the presence of a particular insulin.
. Conclusion
A simple, qualitative assay has been successfully developed and
alidated for the determination of insulin analogues. Employing the
ombination of MW ﬁltration and IAP on an ELISA plate resulted in
ery clean extracts and enabled the detection of the insulin ana-
ogues in all of the collected excretion samples. The main beneﬁts
f this strategy lie in the reproducibility of the sample prepara-
ion step and in the use of conventional chromatographic and mass
pectrometric systems offering a promising tool to the arsenal of
vailable insulin assays and easy method transfer to other labora-
ories.sence of insulin Aspart, Glargine, Glulisine and Lispro in the excretion and spiked
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